E.g., 08/15/2022
E.g., 08/15/2022

bioMérieux Receives Emergency Use Authorization for Its VIDAS® SARS-CoV-2 Antibody Serology Tests

07 August, 2020

bioMérieux has received Emergency Use Authorization by the U.S. Food and Drug Administration of its VIDAS® SARS-COV-2 IgM and VIDAS® SARS-COV-2 IgG serology tests.

bioMérieux Continues to Win Numerous Industry Awards for Outstanding Service and Performance

21 July, 2020

bioMérieux has recently been recognized with six IMV ServiceTrak™ Clinical awards for Blood Culture and ID/AST excellence.

Launch of BIOFIRE® MYCOPLASMA test for mycoplasma detection in biopharmaceutical products

16 July, 2020

bioMérieux announces the launch of BIOFIRE® MYCOPLASMA, an innovative test for mycoplasma detection in pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.), the most vibrant sector in the pharmaceutical industry.

BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked

15 July, 2020

bioMérieux announced the CE marking of BIOFIRE® Respiratory Panel 2.1 plus (RP2.1plus) tests for detection of 23 pathogens, including SARS-CoV-2.

bioMérieux 2019 Annual Report

13 July, 2020

In guiding the Company’s development, bioMérieux has always focused on meeting healthcare challenges related to infectious diseases all over the world. With over 90% of sales outside of France today, the scope of our activity is geographically balanced.

bioMérieux – Second-Quarter 2020 Business Performance Preannoucement

09 July, 2020

Marcy l'Étoile (France), July 9, 2020 – In light of the withdrawal of its annual objectives, bioMérieux, a world leader in the field of in vitro diagnostics, today announced preliminary quarterly information about its business activity ending June 30, 2020.

bioMérieux receives FDA clearance to extend platelet shelf life to 7 days with Large Volume Delayed Sampling strategy using BACT/ALERT® 3D and BACT/ALERT® VIRTUO® culture systems.

22 May, 2020

bioMérieux announces that its BACT/ALERT® BPA and BPN culture bottles have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Large Volume Delayed Sampling (LVDS) of leukocyte-reduced apheresis platelets (LRAP) and leukocyte-reduced whole blood platelet concentrates (LRWBPC) with BACT/ALERT®3D and BACT/ALERT® VIRTUO® systems.

CE marking of bioMérieux serology tests for SARS-CoV-2 on VIDAS®

21 May, 2020

bioMérieux announced the CE marking of VIDAS anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to SARS-CoV-2 which causes the COVID-19 disease.

Memorial Day Shipping Schedule

12 May, 2020

Please be advised that major delivery services in the U.S. will be closed on Monday, May 25, 2020 in observance of the Memorial Day holiday. We encourage you to place orders with the following dates in mind.

bioMérieux serology tests for SARS-CoV-2 on VIDAS® undergo validation preceding imminent launch

06 May, 2020

bioMérieux announces the upcoming launch of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to the SARS-CoV-2, complementing its existing COVID-19 solutions.

Pioneering Diagnostics